OVID
HealthcareOvid Therapeutics Inc.
$1.66
$-0.10 (-5.68%)
Jan 5, 2026
Price History (1Y)
Analysis
Ovid Therapeutics Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $118.21 million and 23 employees. Its industry classification aligns with that of its peers within the broader biotechnology segment. The company's financial health indicates significant losses, with net income totaling -$35,872,000 and EBITDA standing at -$38,652,000 in the trailing twelve months. Operating margin is reported as -9487.1%, while profit margin is 0.0%. Return on Equity (ROE) is -60.1%, and Return on Assets (ROA) stands at -29.3%. The company maintains a significant cash balance of $25.60 million, accompanied by debt of $13.76 million, resulting in a debt to equity ratio of 30.79. Ovid Therapeutics Inc.'s valuation metrics are characterized by a forward P/E ratio of -4.47 and an EV/EBITDA ratio of -2.94. Revenue growth has decreased by -23.7% year-over-year. The company does not currently pay dividends, resulting in a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Visit website →Key Statistics
- Market Cap
- $118.21M
- P/E Ratio
- N/A
- 52-Week High
- $2.01
- 52-Week Low
- $0.24
- Avg Volume
- 1.80M
- Beta
- 0.22
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 23